This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Biocytogen Pharmaceuticals (Beijing)

Profile

Company/Organization Description or Summary

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company that drives the research and development of new drugs with innovative technologies. Biocytogen is committed to becoming a global headstream of new drugs to bring benefits to patients worldwide. Based on proprietary fully human antibody RenMab™ and RenLite™ mice for fully human antibody production with robust humoral responses, highly diverse antibody repertoires and superior affinity, Biocytogen has integrated its platforms in monoclonal (mAb) and bispecific antibody (BsAb) development platforms, in vivo drug efficacy screening platforms and strong clinical development ability to streamline the entire drug development process. Biocytogen has launched Project Integrum, the world’s first large-scale antibody discovery screening program adopting an evidence-based in vivo efficacy screening methodology to concurrently generate and screen antibodies against over 1,000 potential druggable targets, most of which have not been explored in clinical trials yet. With the implementation of Project Integrum, Biocytogen has entered ongoing collaborations with dozens of partners worldwide to produce many first-in-class and/or best-in-class antibody drugs. Biocytogen’s pipeline includes 12 core products among which 2 products are in phase II multi-regional clinical trials (MRCTs) and 2 products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.